Should You Buy Cemex SAB de CV (CX) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
12.830
1 Day change
-2.58%
52 Week Range
13.350
Analysis Updated At
2026/01/28
BUY. For a beginner long-term investor with $50k–$100k who doesn’t want to wait for a perfect dip, CX looks like a good buy right now: the trend is bullish (stacked moving averages + expanding positive MACD), Wall Street sentiment has recently turned more positive with multiple upgrades/target raises, and options positioning is strongly call-skewed (bullish). The main trade-off is that the stock is a bit stretched short-term (RSI elevated and price near resistance) and the most recent quarter showed weaker bottom-line results despite revenue/margin improvement.
Technical Analysis
Trend is bullish. The moving averages are positively stacked (SMA_5 > SMA_20 > SMA_200), which supports an ongoing uptrend. MACD histogram is positive (0.0232) and expanding, reinforcing upward momentum. RSI_6 is high at 75.21, implying the stock is extended in the short run even though the provided label says “neutral.” Price levels: Pivot/support sits around 12.754 (with S1 ~12.414), while resistance is close overhead at R1 13.094 and R2 13.304. With the post-market price at 13.17, CX is already above R1 and approaching R2, meaning upside may be choppier near-term, but the broader technical structure remains constructive.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Options sentiment is strongly bullish: open interest put-call ratio of 0.04 and volume put-call ratio of 0.06 indicate calls dominate positioning and trading activity. Implied volatility is relatively low (30D IV 33.89) with a low IV percentile (8.4) and IV rank (4.41), suggesting options are priced with comparatively low fear. Today’s option volume is elevated versus its 30-day average (14.99x), reinforcing that traders are actively leaning into the name on the call side.
Technical Summary
Sell
2
Buy
8
Positive Catalysts
- Recent Wall Street sentiment improvement: multiple upgrades and price target raises.
- Barclays (2026-01-27) raised PT to $15 and reiterated Overweight, citing margin and cash-led earnings growth potential.
- Upcoming earnings catalyst: QDEC 2025 earnings on 2026-02-10 (pre-market).
Neutral/Negative Catalysts
- Short-term extension risk: RSI_6 at 75.21 and price trading near/into resistance (R2 ~13.304).
- Latest reported quarter showed weaker profitability despite revenue growth (net income and EPS down materially YoY).
- No supportive near-term news flow in the past week (no fresh external catalyst beyond the upcoming earnings event).
- Hedge funds and insiders show neutral activity (no strong “smart money” trend signal from the provided data).
Financial Performance
Latest quarter provided: 2025/Q3. Revenue rose to 4,245,421,000 (+4.70% YoY) and gross margin improved to 33.58 (+2.16% YoY), which is a constructive operating trend. However, profitability weakened: net income fell to 263,699,000 (-35.00% YoY) and EPS fell to 0.02 (-33.33% YoY). Overall: top-line and margin improvement is positive for long-term durability, but the bottom-line decline is a clear near-term fundamental drawback to monitor into the QDEC 2025 earnings release on 2026-02-10.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analyst trend has improved materially over the past ~2 months: RBC upgraded to Sector Perform (2025-12-08) with a higher PT ($11.25 from $8.25), BBVA upgraded to Outperform (2026-01-09) with MXN 27.50 PT, and Barclays reiterated Overweight while raising PT to $15 (2026-01-27). Wall Street pros: expectations for margin/cash-led earnings growth, pricing discipline, and cost normalization; more constructive macro/backdrop implied by the upgrades. Cons: the story depends on execution (margin/cash delivery) while volumes may be muted, and the latest quarter showed notable profit/EPS pressure. Politician/congress activity: no recent congress trading data available in the last 90 days.
Wall Street analysts forecast CX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CX is 11.43 USD with a low forecast of 11.1 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CX is 11.43 USD with a low forecast of 11.1 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 13.170
Low
11.1
Averages
11.43
High
12
Current: 13.170
Low
11.1
Averages
11.43
High
12
Barclays
Benjamin Theurer
Overweight
maintain
$12 -> $15
AI Analysis
2026-01-27
New
Reason
Barclays
Benjamin Theurer
Price Target
$12 -> $15
AI Analysis
2026-01-27
New
maintain
Overweight
Reason
Barclays analyst Benjamin Theurer raised the firm's price target on Cemex to $15 from $12 and keeps an Overweight rating on the shares ahead of the Q4 report. The company is well positioned for margin and cash-led earnings growth, with pricing discipline and cost normalization expected to offset muted volumes, the analyst tells investors in a research note.
BBVA
Market Perform -> Outperform
upgrade
$27.50
2026-01-09
Reason
BBVA
Price Target
$27.50
2026-01-09
upgrade
Market Perform -> Outperform
Reason
BBVA upgraded Cemex to Outperform from Market Perform with a MXN 27.50 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CX
